Rare Disease Day With Amy DeZern, MD, MHS: Making Progress in Myelodysplastic Syndromes
Keira Smith
Expert Analysis
Amy DeZern, MD, MHS. In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Amy DeZern, MD, MHS, Director of the Bone Marrow Failure and Myelodysplastic Syndromes (MDS) Program at Johns Hopkins Medicine and member of the Aplastic Anemia and MDS International Foundation (AAMDSIF) medical advisory board. In this interview, Dr. DeZern explains the challenges of treating such a rare disease and shares some of recent promising updates in novel treatments for patients with MDS. This interview has been conducted in partnership with AAMDSIF, the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, MDS, paroxysmal nocturnal hemoglobinuria, and related bone marrow failure diseases. The Foundation provides answers, support, and hope to thousands of patients and their families around the world.
Navigating the Surgical Approach to Gastric Cancers With Ryan Fields, MD, FACP
Keira Smith
Expert Analysis
For patients with gastric and gastroesophageal cancers, questions remain in the optimal approaches to treatment and surgery. At the recent American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Ryan Fields, MD, Chief of the Section of Surgical Oncology at Washington University School of Medicine and the Alvin J. Siteman Ca...
World Cancer Day: An Expert Panel Discussion With Thomas Abrams, MD; Ulka Vaishampayan, MD; and Beth Sandy, MSN, CRNP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · World Cancer Day With Thomas Abrams, MD; Ulka Vaishampayan, MD; and Beth Sandy, MSN, CRNP In honor of World Cancer Day, members of the Oncology Data Advisor (ODA) editorial board gathered to discuss the latest advances and future directions in oncology research. Dr. Thomas Abrams, an Assistant Professor of Medicine at Harvard Medical School shared recent progress in the field of gastrointestinal cancers; Dr. Ulka Vaishampayan, a Professor of Internal Medicine at the University of Michigan Rogel Cancer Center provided insights into current trends in genitourinary cancer research; and Beth Sandy, MSN, CRNP, an outpatient thoracic oncology nurse practitioner at the University of Pennsylvania Abramson Cancer Center, discussed recent and future treatment advances in the field of lung cancer.  
Can Digital Life Coaching During Transplant for Multiple Myeloma Improve Quality of Life? Insights From Rahul Banerjee, MD, and Kelly Brassil, PhD, RN, FAAN
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Can Digital Life Coaching Improve Quality of Life in Transplant? Rahul Banerjee and Kelly Brassil Patients undergoing autologous stem cell transplant (ASCT) for multiple myeloma face significant challenges in quality of life, including anxiety, acute symptom burden, and decreased physical function. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Rahul Banerjee and Dr. Kelly Brassil presented their research regarding digital life coaching for this patient population. In this interview with Oncology Data Advisor, Dr. Banerjee and Dr. Brassil discuss their results from a prior pilot study on this topic, the design of an ongoing phase 2 trial to continue the research, and its implications for improving the quality of life for patients undergoing ASCT for multiple myeloma.  
World Cancer Day: An Expert Panel Discussion With Thomas Abrams, MD; Ulka Vaishampayan, MD; and Beth Sandy, MSN, CRNP
Keira Smith
Expert Analysis
In honor of World Cancer Day, members of the Oncology Data Advisor (ODA) editorial board gathered to discuss the latest advances and future directions in oncology research. Dr. Thomas Abrams, an Assistant Professor of Medicine at Harvard Medical School shared recent progress in the field of gastrointestinal cancers; Dr. Ulka Vaishampayan, a Professor of Internal Medicine at the University of Michigan Rogel Cancer Center provided insights into current trends in genitourinary cancer research; and Beth Sandy, MSN, CRNP, an outpatient thoracic oncology nurse practitioner at the University of Pennsylvania Abramson Cancer Center, discussed recent and future treatment advances in the field of lung cancer.  
Cabozantinib/Atezolizumab and the Future of Metastatic Colorectal Cancer Treatment: Thomas Abrams, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.  
Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer With Mark Kris, MD, and Victoria Sherry, DNP, CRNP, AOCNP®
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer Squamous cell lung carcinoma is a distinct histologic subtype of non–small cell lung cancer (NSCLC) that accounts for approximately 25% to 30% of all NSCLC cases and is associated with approximately 30% shorter survival compared with other ...
Can Digital Life Coaching During Transplant for Multiple Myeloma Improve Quality of Life? Insights From Rahul Banerjee, MD, and Kelly Brassil, PhD, RN, FAAN
Keira Smith
Expert Analysis
Rahul Banerjee, MD, and Kelly Brassil, PhD, RN, FAAN. Patients undergoing autologous stem cell transplant (ASCT) for multiple myeloma face significant challenges in quality of life, including anxiety, acute symptom burden, and decreased physical function. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Rahul Banerjee and Dr. Kelly Brassil presented their research regarding digital life coaching for this patient population. In this interview with Oncology Data Advisor, Dr. Banerjee and Dr. Brassil discuss their results from a prior pilot study on this topic, the design of an ongoing phase 2 trial to continue the research, and its implications for improving the quality of life for patients undergoing ASCT for multiple myeloma.  
Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In the Presidential Symposium at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Matthew Davids of Harvard Medical School discussed the current therapeutic strategies used to inhibit or reactivate mutant p53 in the treatment of hematologic malignancies. In this interview with Oncology Data Advisor, Dr. Davids delves further into the latest research in p53-directed therapeutic strategies and the future of targeting this specific mutation.  
The Call to Understand Racial and Socioeconomic Disparities in Pediatric Acute Lymphoblastic Leukemia: Sumit Gupta, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Call to Understand Racial Disparities in Pediatric Acute Lymphoblastic Leukemia: Sumit Gupta, MD Although survival in childhood acute lymphoblastic leukemia (ALL) has improved over the years, there remains a need to identify racial, ethnic, and socioeconomic health disparities that contribute to poor outcomes. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, a team of researchers led by Dr. Sumit Gupta of the University of Toronto investigated the impact of race, ethnicity, and socioeconomic status among young patients with ALL enrolled in Children's Oncology Group studies between 2004 and 2019. The investigators identified significant disparities in survival outcomes in association with these factors. In this interview, Dr. Gupta explains the importance of recognizing health disparities among pediatric patients with ALL and the changes that can be implemented to address them.  
Cabozantinib/Atezolizumab and the Future of Metastatic Colorectal Cancer Treatment: Thomas Abrams, MD
Keira Smith
Expert Analysis
Thomas Abrams, MD. Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.  
Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc
Keira Smith
Expert Analysis
Matthew Davids, MD, MMSc. Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In the Presidential Symposium at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Matthew Davids of Harvard Medical School discussed the current therapeutic strategies used to inhibit or reactivate mutant p53 in the treatment of hematologic malignancies. In this interview with Oncology Data Advisor, Dr. Davids delves further into the latest research in p53-directed therapeutic strategies and the future of targeting this specific mutation.  
The Call to Understand Racial and Socioeconomic Disparities in Pediatric Acute Lymphoblastic Leukemia: Sumit Gupta, MD
Keira Smith
Expert Analysis
Although survival in childhood acute lymphoblastic leukemia (ALL) has improved over the years, there remains a need to identify racial, ethnic, and socioeconomic health disparities that contribute to poor outcomes. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, a team of researchers l...
The Burden of Myelosuppressive Hematologic Adverse Events in Small Cell Lung Cancer: Jerome Goldschmidt, MD
Keira Smith
Expert Analysis
For patients with extensive-stage small cell lung cancer (SCLC), cytotoxic chemotherapy remains a mainstay of treatment. However, myelosuppressive hematologic adverse events such as anemia, neutropenia, and thrombocytopenia pose a significant challenge to care. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Me...
Lisocabtagene Maraleucel and the Transforming Treatment Landscape for Large B-Cell Lymphoma: Manali Kamdar, MD
Keira Smith
Expert Analysis
For patients with relapsed/refractory large B-cell lymphoma (LBCL), treatment options are limited, and outcomes remain poor with the current standard of care. In the phase 3 TRANSFORM trial, Dr. Manali Kamdar, Clinical Director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, and colleagues investigated the efficacy o...
Reducing Racial and Ethnic Disparities in Clinical Trial Enrollment for Acute Lymphoblastic Leukemia: Lori Muffly, MD, MS
Keira Smith
Expert Analysis
Compared with the non-Hispanic White population, Hispanic and Black adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) experience significantly inferior outcomes. In an analysis of the CALGB 10403 AYA trial presented at the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, ...
Addressing Racial Disparities in Clinical Trial Recruitment: Alexis A. Thompson, MD, MPH
Keira Smith
Expert Analysis
One of the issues surrounding hematology care is the underrepresentation of racial and ethnic minorities in clinical trials. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Alexis A. Thompson, MD, MPH, past President of ASH and Professor of Pediatrics at Northwestern University's Feinberg...
Axicabtagene Ciloleucel and Increasing Accessibility to CAR T-Cell Therapy With Frederick Locke, MD
Keira Smith
Expert Analysis
While the current standard of care for relapsed/refractory large B-cell lymphoma is high-dose therapy with autologous stem cell rescue, many patients do not respond to or cannot tolerate high-dose therapy. As a result, outcomes for second-line treatment remain poor. At the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposi...
Polatuzumab Vedotin Plus R-CHP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: John Burke, MD
Keira Smith
Expert Analysis
For patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), less than half of patients are cured with the current standard of care, and effective treatments are greatly needed. In the phase 3 POLARIX trial, a team of researchers investigated the efficacy of polatuzumab vedotin in combination with R-CHP (rituximab/cyclophosphamide/doxor...
Duvelisib/Romidepsin for Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Steven M. Horwitz, MD
Keira Smith
Expert Analysis
For patients with relapsed/refractory T-cell lymphoma (TCL), standard therapies provide an overall response rate of only 25% to 35%, and novel therapeutic options are greatly needed. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. St...

Copyright © 2022 Oncology Data Advisor. All rights reserved.